Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All molnupiravir studies
 
Feedback
Home
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 molnupiravir studies

Outcomes in molnupiravir studies. Potential risks include the creation of dangerous variants and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity Chamod, Gruber, Hadj Hassine, Huntsman, Marikawa, Standing, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson, twitter.com. There is substantial publication bias. Multiple trials have not reported results and did not respond to requests Lawrence.
0 0.5 1 1.5+ All studies 13% 41 137,199 Improvement, Studies, Patients Relative Risk Mortality 20% 19 110,741 Ventilation 22% 7 24,432 ICU admission 7% 6 28,347 Hospitalization 2% 18 79,431 Progression 25% 5 33,432 Recovery 12% 11 28,091 Cases 24% 1 1,527 Viral clearance 25% 13 9,337 RCTs 27% 17 33,504 RCT mortality 25% 5 27,878 Peer-reviewed 16% 30 108,125 Prophylaxis 24% 1 1,527 Early 14% 33 94,449 Late 11% 7 41,223 Molnupiravir for COVID-19 c19early.org June 2024 after exclusions Favorsmolnupiravir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau​2 = 0.08, I​2 = 81.9%, p = 0.053 Early treatment 14% 0.86 [0.74-1.00] 297/32,494 590.0/61,955 14% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 11% 0.89 [0.84-0.93] 775/9,553 2,599/31,670 11% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 13% 0.87 [0.78-0.96] 1,150/42,810 3,292.0/94,389 13% lower risk 41 molnupiravir COVID-19 studies c19early.org June 2024 Tau​2 = 0.04, I​2 = 78.8%, p = 0.0064 Effect extraction pre-specified 1 OT: comparison with other treatment2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau​2 = 0.07, I​2 = 81.2%, p = 0.0075 Early treatment 19% 0.81 [0.70-0.95] 278/31,250 555.0/56,897 19% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 11% 0.89 [0.84-0.93] 775/9,553 2,599/31,670 11% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 16% 0.84 [0.76-0.93] 1,131/41,566 3,257.0/89,331 16% lower risk 39 molnupiravir COVID-19 studies after exclusions c19early.org June 2024 Tau​2 = 0.03, I​2 = 77.8%, p = 0.00076 Effect extraction pre-specified 1 OT: comparison with other treatment2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Wong (PSM) 52% 0.48 [0.40-0.59] 1,856 (n) 1,856 (n) Flisiak 39% 0.61 [0.38-0.97] 20/203 63/387 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] 2/230 3/690 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] Bajema (PSM) 18% 0.82 [0.52-1.29] 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] 0/84 1/210 Goodwin -110% 2.10 [0.19-22.9] 1/80 2/336 Cheng 15% 0.85 [0.77-0.95] 4,146 (n) 5,792 (n) Tau​2 = 0.13, I​2 = 77.8%, p = 0.041 Early treatment 26% 0.74 [0.55-0.99] 81/24,604 284.0/44,914 26% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] 57/445 55/478 Tau​2 = 0.00, I​2 = 6.6%, p < 0.0001 Late treatment 11% 0.89 [0.84-0.94] 775/9,553 2,599/31,670 11% lower risk All studies 20% 0.80 [0.69-0.93] 856/34,157 2,883.0/76,584 20% lower risk 19 molnupiravir COVID-19 mortality results c19early.org June 2024 Tau​2 = 0.04, I​2 = 75.5%, p = 0.0037 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 58% 0.42 [0.17-1.01] 1,856 (n) 1,856 (n) Improvement, RR [CI] Treatment Control Flisiak 5% 0.95 [0.39-2.32] 7/203 14/387 Suzuki (PSM) 57% 0.43 [0.02-10.5] 0/230 1/690 Wong (PSM) 60% 0.40 [0.19-0.84] Bajema (PSM) 17% 0.83 [0.17-4.12] 3/897 3.6/897 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0083 Early treatment 46% 0.54 [0.34-0.85] 10/3,186 18.6/3,830 46% lower risk Wan -7% 1.07 [0.89-1.30] 2,700 (n) 13,795 (n) Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) -43% 1.43 [0.50-4.08] 8/445 6/476 Tau​2 = 0.00, I​2 = 0.0%, p = 0.43 Late treatment -8% 1.08 [0.90-1.30] 8/3,145 6/14,271 8% higher risk All studies 22% 0.78 [0.51-1.19] 18/6,331 24.6/18,101 22% lower risk 7 molnupiravir COVID-19 mechanical ventilation results c19early.org June 2024 Tau​2 = 0.12, I​2 = 43.6%, p = 0.25 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 26% 0.74 [0.45-1.21] Improvement, RR [CI] Treatment Control Liu -162% 2.62 [0.11-60.6] 1/26 0/16 Bajema (PSM) 1% 0.99 [0.41-2.37] 10/897 10.1/897 Cheng 12% 0.88 [0.59-1.30] 4,146 (n) 5,792 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.26 Early treatment 15% 0.85 [0.63-1.13] 11/5,069 10.1/6,705 15% lower risk Wan -2% 1.02 [0.76-1.36] 2,700 (n) 13,795 (n) Improvement, RR [CI] Treatment Control Özdemir 0% 1.00 [0.15-6.75] 2/39 2/39 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -2% 1.02 [0.76-1.36] 2/2,739 2/13,834 2% higher risk All studies 7% 0.93 [0.76-1.14] 13/7,808 12.1/20,539 7% lower risk 6 molnupiravir COVID-19 ICU results c19early.org June 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 6% 0.94 [0.89-1.00] hosp. time 1,856 (n) 1,856 (n) Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Flisiak -1% 1.01 [0.71-1.43] hosp. time 203 (n) 387 (n) AGILE CST-2 Khoo (DB RCT) 89% 0.11 [0.01-2.03] hosp. 0/90 4/90 Arbel 65+ 45% 0.55 [0.34-0.88] hosp. 18/845 513/12,724 Arbel 40-64 -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -7% 1.07 [0.81-1.41] hosp. 103/12,529 96/12,525 Wong (PSM) 2% 0.98 [0.89-1.06] hosp. Liu 18% 0.82 [0.63-1.06] hosp. time 26 (n) 16 (n) Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Bajema (PSM) -30% 1.30 [1.01-1.68] hosp. 162/897 124.3/897 Inaba -127% 2.27 [0.60-7.25] hosp. 5/84 8/210 Goodwin 58% 0.42 [0.05-3.23] hosp. 1/80 10/336 Tau​2 = 0.02, I​2 = 69.9%, p = 0.6 Early treatment 3% 0.97 [0.86-1.09] 331/19,005 917.3/36,990 3% lower risk Wan 1% 0.99 [0.93-1.05] hosp. 2,298/6,153 2,541/17,283 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Late treatment 1% 0.99 [0.93-1.05] 2,298/6,153 2,541/17,283 1% lower risk All studies 2% 0.98 [0.90-1.08] 2,629/25,158 3,458.3/54,273 2% lower risk 18 molnupiravir COVID-19 hospitalization results c19early.org June 2024 Tau​2 = 0.01, I​2 = 68.1%, p = 0.73 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Tau​2 = 0.07, I​2 = 81.7%, p = 0.085 Early treatment 13% 0.87 [0.74-1.02] 241/32,106 486.0/61,603 13% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Tau​2 = 0.00, I​2 = 6.6%, p < 0.0001 Late treatment 11% 0.89 [0.84-0.94] 775/9,553 2,599/31,670 11% lower risk All studies 11% 0.89 [0.80-0.99] 1,016/41,659 3,085.0/93,273 11% lower risk 33 molnupiravir COVID-19 serious outcomes c19early.org June 2024 Tau​2 = 0.03, I​2 = 79.7%, p = 0.028 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.98] recovery 709 (n) 699 (n) Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) -12% 1.12 [0.71-1.79] no recov. 27/90 24/90 PANORAMIC Butler (RCT) 22% 0.78 [0.75-0.81] no recov. 3,856/12,403 4,838/12,140 Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Tau​2 = 0.01, I​2 = 44.4%, p = 0.00027 Early treatment 19% 0.81 [0.72-0.91] 3,895/13,669 4,870/13,352 19% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 MOVe-IN Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) RECOVERY Horby (RCT) -9% 1.09 [0.88-1.35] no disch. 126/445 124/478 Tau​2 = 0.00, I​2 = 0.0%, p = 0.53 Late treatment -6% 1.06 [0.89-1.26] 126/517 124/553 6% higher risk All studies 12% 0.88 [0.78-0.99] 4,021/14,186 4,994/13,905 12% lower risk 11 molnupiravir COVID-19 recovery results c19early.org June 2024 Tau​2 = 0.01, I​2 = 55.0%, p = 0.031 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk 1 molnupiravir COVID-19 case result c19early.org June 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 MOVe-OUT Jayk Ber.. (DB RCT) 4% 0.96 [0.90-1.02] viral load 518 (n) 510 (n) Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Wong (PSM) 28% 0.72 [0.61-0.87] viral+ 1,856 (n) 1,856 (n) Zou (RCT) 10% 0.90 [0.83-0.97] viral time 76 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) 23% 0.77 [0.58-1.09] viral+ 90 (n) 90 (n) PANORAMIC Butler (RCT) -95% 1.95 [1.15-3.31] viral load 21 (n) 11 (n) Liu 21% 0.79 [0.59-1.05] viral time 26 (n) 16 (n) Sinha (RCT) 48% 0.52 [0.42-0.63] viral load 608 (n) 610 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau​2 = 0.06, I​2 = 89.2%, p = 0.0006 Early treatment 27% 0.73 [0.60-0.87] 96/4,215 208/4,087 27% lower risk MOVe-IN Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) 12% 0.88 [0.85-0.91] viral load 445 (n) 478 (n) Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 12% 0.88 [0.85-0.91] 26/497 34/538 12% lower risk All studies 25% 0.75 [0.67-0.85] 122/4,712 242/4,625 25% lower risk 13 molnupiravir COVID-19 viral clearance results c19early.org June 2024 Tau​2 = 0.03, I​2 = 87.1%, p < 0.0001 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau​2 = 0.21, I​2 = 50.0%, p = 0.012 Early treatment 41% 0.59 [0.39-0.89] 83/15,445 182/15,318 41% lower risk 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Late treatment -10% 1.10 [0.83-1.46] 68/661 56/553 10% higher risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 27% 0.73 [0.54-0.99] 229/16,869 341/16,635 27% lower risk 17 molnupiravir COVID-19 Randomized Controlled Trials c19early.org June 2024 Tau​2 = 0.18, I​2 = 61.4%, p = 0.043 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] 3/12,529 5/12,525 Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Early treatment 67% 0.33 [0.11-0.99] 4/13,378 15/13,286 67% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] 57/445 55/478 Tau​2 = 0.21, I​2 = 27.3%, p = 0.51 Late treatment -35% 1.35 [0.56-3.26] 68/661 56/553 35% higher risk All studies 25% 0.75 [0.30-1.90] 72/14,039 71/13,839 25% lower risk 5 molnupiravir COVID-19 RCT mortality results c19early.org June 2024 Tau​2 = 0.49, I​2 = 48.0%, p = 0.56 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Tau​2 = 0.06, I​2 = 77.5%, p = 0.02 Early treatment 17% 0.83 [0.70-0.97] 216/29,327 289/36,971 17% lower risk MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 12% 0.88 [0.84-0.93] 718/9,108 2,544/31,192 12% lower risk MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.049 Prophylaxis 24% 0.76 [0.57-1.01] 78/763 103/764 24% lower risk All studies 16% 0.84 [0.76-0.93] 1,012/39,198 2,936/68,927 16% lower risk 30 molnupiravir COVID-19 peer reviewed studies c19early.org June 2024 Tau​2 = 0.02, I​2 = 75.2%, p = 0.00077 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.01-0.75] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.01-0.83] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Khoo (RCT) -100% 2.00 [0.28-14.2] no recov. 4/12 1/6 Khoo (RCT) -100% 2.00 [0.90-4.43] no recov. 4/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Khoo (RCT) -200% 3.00 [0.39-23.1] no recov. 2/4 1/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 MOVe-OUT Jayk Ber.. (DB RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 MOVe-OUT Jayk Ber.. (DB RCT) 30% 0.70 [0.48-1.00] death/hosp. 48/709 68/699 MOVe-OUT Jayk Ber.. (DB RCT) 94% 0.06 [0.00-0.97] death/hosp. 0/37 9/47 MOVe-OUT Jayk Ber.. (DB RCT) 50% 0.50 [0.20-1.26] death/hosp. 6/75 13/82 MOVe-OUT Jayk Ber.. (DB RCT) 24% 0.76 [0.42-1.38] death/hosp. 18/237 22/221 MOVe-OUT Jayk Ber.. (DB RCT) 42% 0.58 [0.20-1.68] death/hosp. 5/47 7/38 MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.98] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 19% 0.81 [0.71-0.92] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 15% 0.85 [0.75-0.97] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 14% 0.86 [0.76-0.97] recovery 709 (n) 699 (n) MOVe-OUT Jayk Ber.. (DB RCT) 4% 0.96 [0.90-1.02] viral load 518 (n) 510 (n) MOVe-OUT Jayk Ber.. (DB RCT) -2% 1.02 [0.97-1.08] viral load 516 (n) 513 (n) MOVe-OUT Jayk Ber.. (DB RCT) 1% 0.99 [0.93-1.05] viral load 515 (n) 506 (n) MOVe-OUT Jayk Ber.. (DB RCT) 13% 0.87 [0.79-0.95] viral load 558 (n) 547 (n) MOVe-OUT Jayk Ber.. (DB RCT) 17% 0.83 [0.71-0.97] viral load 570 (n) 570 (n) Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Tippabhotla (RCT) 46% 0.54 [0.41-0.71] no improv. 67/610 125/610 Tippabhotla (RCT) 52% 0.48 [0.42-0.54] no improv. 199/610 417/610 Tippabhotla (RCT) 25% 0.75 [0.71-0.79] no improv. 433/610 576/610 Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Tippabhotla (RCT) 81% 0.19 [0.15-0.24] viral+ 62/610 327/610 Tippabhotla (RCT) 78% 0.22 [0.19-0.27] viral+ 113/610 505/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Wong (PSM) 58% 0.42 [0.17-1.01] ventilation 1,856 (n) 1,856 (n) Wong (PSM) 40% 0.60 [0.52-0.69] progression 1,856 (n) 1,856 (n) Wong (PSM) 6% 0.94 [0.89-1.00] hosp. time 1,856 (n) 1,856 (n) Wong (PSM) 28% 0.72 [0.61-0.87] viral+ 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Zou (RCT) 29% 0.71 [0.28-1.85] recov. time 77 (n) 31 (n) Zou (RCT) 10% 0.90 [0.83-0.97] viral time 76 (n) 31 (n) Zou (RCT) 51% 0.49 [0.28-0.84] viral+ 18/76 15/31 Zou (RCT) 37% 0.63 [0.51-0.78] viral+ 45/76 29/31 Zou (RCT) 18% 0.82 [0.73-0.92] viral+ 62/76 31/31 Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 Flisiak 5% 0.95 [0.39-2.32] ventilation 7/203 14/387 Flisiak -1% 1.01 [0.71-1.43] hosp. time 203 (n) 387 (n) AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 AGILE CST-2 Khoo (DB RCT) 89% 0.11 [0.01-2.03] hosp. 0/90 4/90 AGILE CST-2 Khoo (DB RCT) -12% 1.12 [0.71-1.79] no recov. 27/90 24/90 AGILE CST-2 Khoo (DB RCT) 23% 0.77 [0.58-1.09] viral+ 90 (n) 90 (n) Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Najjar-Deb.. (PSM) 17% 0.83 [0.57-1.21] progression 50/2,661 60/2,661 Najjar-Deb.. (PSM) 25% 0.75 [0.51-1.12] severe case 43/2,661 57/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 65+ -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Arbel 65+ 45% 0.55 [0.34-0.88] hosp. 18/845 513/12,724 Arbel 65+ -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Arbel 40-64 -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Suzuki (PSM) 57% 0.43 [0.02-10.5] ventilation 0/230 1/690 Suzuki (PSM) 53% 0.47 [0.22-0.98] progression 9/230 58/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 PANORAMIC Butler (RCT) -6% 1.06 [0.81-1.41] death/hosp. 105/12,529 98/12,525 PANORAMIC Butler (RCT) -7% 1.07 [0.81-1.41] hosp. 103/12,529 96/12,525 PANORAMIC Butler (RCT) 2% 0.98 [0.94-1.01] transmission 3,887/10,803 3,873/10,548 PANORAMIC Butler (RCT) 22% 0.78 [0.75-0.81] no recov. 3,856/12,403 4,838/12,140 PANORAMIC Butler (RCT) 19% 0.81 [0.78-0.83] recov. time 12,403 (n) 12,140 (n) PANORAMIC Butler (RCT) 30% 0.70 [0.67-0.73] no recov. 2,675/12,403 3,766/12,140 PANORAMIC Butler (RCT) 26% 0.74 [0.71-0.76] recov. time 12,403 (n) 12,140 (n) PANORAMIC Butler (RCT) -95% 1.95 [1.15-3.31] viral load 21 (n) 11 (n) PANORAMIC Butler (RCT) 92% 0.08 [0.05-0.14] viral load 33 (n) 26 (n) Wong (PSM) 24% 0.76 [0.61-0.95] death Wong (PSM) 60% 0.40 [0.19-0.84] ventilation Wong (PSM) 26% 0.74 [0.45-1.21] ICU Wong (PSM) 2% 0.98 [0.89-1.06] hosp. Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Liu 8% 0.92 [0.17-4.94] progression 3/26 2/16 Liu 18% 0.82 [0.63-1.06] hosp. time 26 (n) 16 (n) Liu 21% 0.79 [0.59-1.05] viral time 26 (n) 16 (n) Liu -23% 1.23 [0.12-12.5] viral+ 2/26 1/16 Liu 28% 0.72 [0.29-1.76] viral+ 7/26 6/16 Liu 38% 0.62 [0.41-0.92] viral+ 14/26 14/16 Liu 18% 0.82 [0.64-1.05] viral+ 20/26 15/16 Liu 12% 0.88 [0.75-1.05] viral+ 23/26 16/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Sinha (RCT) 53% 0.47 [0.26-0.85] no improv. 16/608 34/610 Sinha (RCT) 48% 0.52 [0.42-0.63] viral load 608 (n) 610 (n) Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Zheng -85% 1.85 [1.14-3.03] death/hosp. 55/2,689 32/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Bajema (PSM) 49% 0.51 [0.20-1.27] death 7/897 13.8/897 Bajema (PSM) 17% 0.83 [0.17-4.12] ventilation 3/897 3.6/897 Bajema (PSM) 1% 0.99 [0.41-2.37] ICU 10/897 10.1/897 Bajema (PSM) -30% 1.30 [1.01-1.68] hosp. 162/897 124.3/897 Bajema (PSM) 9% 0.91 [0.59-1.41] hosp. 37/897 40.5/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Inaba -127% 2.27 [0.60-7.25] death/hosp. 5/84 8/210 Inaba -127% 2.27 [0.60-7.25] hosp. 5/84 8/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Goodwin 58% 0.42 [0.05-3.23] hosp. 1/80 10/336 Goodwin 53% 0.47 [0.11-1.97] hosp. 2/80 18/336 Tazare -9% 1.09 [0.93-1.27] death/hosp. Butt -9% 1.09 [0.73-1.63] death/hosp. 48/1,459 44/1,459 Fung 4% 0.96 [0.93-0.99] PASC population-based cohort LONG COVID Fung 8% 0.92 [0.90-0.94] PASC population-based cohort LONG COVID Tare (RCT) -83% 1.83 [0.69-4.82] no recov. 4/7 5/16 Tare (RCT) 0% 1.00 [0.61-1.63] no recov. 6/8 12/16 Cheng 15% 0.85 [0.77-0.95] death 4,146 (n) 5,792 (n) Cheng -0% 1.00 [0.76-1.33] oxygen 4,146 (n) 5,792 (n) Cheng 12% 0.88 [0.59-1.30] ICU 4,146 (n) 5,792 (n) Standing (RCT) -103% 2.03 [0.52-7.94] viral+ 6/117 3/119 Standing (RCT) 31% 0.69 [0.44-1.07] viral+ 26/249 52/343 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 MOVe-IN Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 MOVe-IN Arribas (DB RCT) -217% 3.17 [0.34-29.8] death 3/71 1/75 MOVe-IN Arribas (DB RCT) -317% 4.17 [0.48-36.4] death 4/72 1/75 MOVe-IN Arribas (DB RCT) -311% 4.11 [0.47-35.9] death 4/73 1/75 MOVe-IN Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) MOVe-IN Arribas (DB RCT) 12% 0.88 [0.61-1.28] no recov. 73 (n) 75 (n) MOVe-IN Arribas (DB RCT) -1% 1.01 [0.69-1.47] no recov. 73 (n) 75 (n) MOVe-IN Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 MOVe-IN Arribas (DB RCT) -2% 1.02 [0.74-1.41] viral+ 29/50 34/60 MOVe-IN Arribas (DB RCT) 21% 0.79 [0.56-1.13] viral+ 27/60 34/60 MOVe-IN Arribas (DB RCT) 8% 0.92 [0.41-2.08] viral+ 9/53 10/54 MOVe-IN Arribas (DB RCT) -48% 1.48 [0.72-3.03] viral+ 14/51 10/54 MOVe-IN Arribas (DB RCT) 21% 0.79 [0.34-1.84] viral+ 8/55 10/54 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Wan 1% 0.99 [0.93-1.05] hosp. 2,298/6,153 2,541/17,283 Wan -4% 1.04 [0.98-1.10] progression 2,300/6,153 2,541/17,283 Wan 13% 0.87 [0.81-0.93] death 2,700 (n) 13,795 (n) Wan -7% 1.07 [0.89-1.30] ventilation 2,700 (n) 13,795 (n) Wan -2% 1.02 [0.76-1.36] ICU 2,700 (n) 13,795 (n) Özdemir -50% 1.50 [0.27-8.49] death 3/39 2/39 Özdemir 0% 1.00 [0.15-6.75] ICU 2/39 2/39 RECOVERY Horby (RCT) -11% 1.11 [0.79-1.58] death 57/445 55/478 RECOVERY Horby (RCT) 7% 0.93 [0.68-1.28] death 74/445 79/478 RECOVERY Horby (RCT) -43% 1.43 [0.50-4.08] ventilation 8/445 6/476 RECOVERY Horby (RCT) -9% 1.09 [0.88-1.35] no disch. 126/445 124/478 RECOVERY Horby (RCT) 12% 0.88 [0.85-0.91] viral load 445 (n) 478 (n) MOVe-AHEAD Alpizar (DB RCT) 24% 0.76 [0.57-1.01] symp. case 78/763 103/764 Molnupiravir COVID-19 outcomes c19early.org June 2024 1 OT: comparison with other treatment2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit